Please assess the completion status of the following clinical trial:

Trial Title: A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patients signed the written informed consent~* Women aged 18-70.~* The pathologic diagnosis of recurrent metastatic triple negative breast cancer ［ER-negative(IHC\<1%), PR-negative(IHC\<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］.~* At least one measuring lesion that conforms to RECIST v1.1 standard.~* The number of chemotherapy lines in the metastatic phase was \<3 line.~* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.~* Have a life expectancy of at least 12 weeks.~* Female Subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 3 months after the last dose of study treatment.~* The patients can swallow pills.~* The results of patients' blood tests are as follows: • Hb≥90g/L; • Plt≥90E+9/L; • Neutrophils≥1.5E+9/L; • ALT and AST ≤ triple of normal upper limit; • TBIL ≤ 1.5 times of normal upper limit; • Creatinine ≤ 1.5 times of normal upper limit.~Exclusion Criteria:~* The subjects had any history of autoimmune disease or any use of systemic glucocorticoid or immunosuppressive medications.~* Subjects with severe allergic reactions to other monoclonal antibodies.~* The subjects had a central nervous system metastases with clinical symptoms.~* History of hypertension and antihypertensive medications are not well controlled.~* A heart condition or disease that is not well controlled.~* Subjects had active infections or recent treatment with a systemic immunostimulatory agent (received within the previous 4 weeks).~* Other clinical trials of drugs were used in the first four weeks of the first medication.~* Subjects with treatment history of anti-angiogenesis drugs or check-point inhibitors.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SHR-1210 +Apatinib daily dosing (Type: EXPERIMENTAL): SHR-1210 200mg(3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, daily dosing (d1-d14)
- SHR-1210+Apatinib intermittent dosing (Type: EXPERIMENTAL): SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, intermittent dosing(Continuous administration for 7 days every 14 days, d1-d7)

Based on this trial design, predict the completion outcome and termination type (if applicable).